Journal article
Homologous but not heterologous COVID-19 vaccine booster elicits IgG4 B-cells and enhanced Omicron subvariant binding
GE Hartley, HA Fryer, PA Gill, I Boo, SJ Bornheimer, PM Hogarth, HE Drummer, RE O’Hehir, ESJ Edwards, MC van Zelm
Npj Vaccines | NATURE PORTFOLIO | Published : 2024
Abstract
Booster vaccinations are recommended to improve protection against severe disease from SARS-CoV-2 infection. With primary vaccinations involving various adenoviral vector and mRNA-based formulations, it remains unclear if these differentially affect the immune response to booster doses. We examined the effects of homologous (mRNA/mRNA) and heterologous (adenoviral vector/mRNA) vaccination on antibody and memory B cell (Bmem) responses against ancestral and Omicron subvariants. Healthy adults who received primary BNT162b2 (mRNA) or ChAdOx1 (vector) vaccination were sampled 1-month and 6-months after their 2nd and 3rd dose (homologous or heterologous) vaccination. Recombinant spike receptor-bi..
View full abstractGrants
Awarded by Monash University
Funding Acknowledgements
We thank Dr. Bruce D. Wines and Ms. Sandra Esparon (Burnet Institute) for technical assistance, Ms. Shir Sun, Mr. Jack Edwards and Ms. Ebony Blight (Monash University) for sample collection and preparation, Drs Aggarwal and Turville for their help with Live virus neutralisation assays, and the staff of ARAFlowcore for flow cytometry support. Supported by an Australian Government Research Training Program Scholarship (G.E.H.), the Australian Government Medical Research Future Fund (MRFF, Project no. 2016108; M.C.v.Z., H.E.D. and R.E.O'H.), an unrestricted research grant from BD Biosciences and the Victorian Operational Infrastructure Support Program received by the Burnet Institute (H.E.D.).